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CYTOGENETIC ABNORMALITIES AND THERAPY-RELATED 
MYELODYSPLASTIC SYNDROMES IN RHEUMATIC DISEASE 
CONOR J. McCARTHY, SUSAN SHELDON, CHARLES W. ROSS, and W. JOSEPH McCUNE 
Objective. To describe the myelodysplastic syn- 
dromes (MDS) and cytogenetic abnormalities that oc- 
cur in patients who have been treated with alkylating 
drugs for their rheumatic disease. 
Methods. Patients with rheumatic disease who 
developed MDS after current or previous treatment with 
alkylating drugs were selected for evaluation by chart 
review and cytogenetic studies. 
Results. Eight patients with rheumatic disease 
(mean age 56.9 years) developed MDS over the study 
period. Seven had received oral cyclophosphamide and 1 
chlorambucil as their main immunosuppressive drug. 
The mean total cumulative dose of cyclophosphamide or 
chlorambucil was 118 gm and 6.5 gm, respectively, over 
a period of 2-10 years. The cytogenetic abnormalities 
included a deletion of all or  part of chromosome 7 in 5 
patients, while 4 had a deletion of part of the long arm 
of chromosome 5. Six of the patients have since died. 
Conclusion. Large cumulative doses of cyclo- 
phosphamide and chlorambucil were associated with 
the development of MDS, the occurrence of abnormali- 
ties of chromosome 5 and/or chromosome 7 deletions, 
and a poor prognosis. 
The occurrence of myelodysplastic syndromes 
(MDS) after exposure to alkylating drugs is frequently 
associated with chromosomal abnormalities, particularly 
of chromosome 5 and/or chromosome 7 (1-3). These 
changes are often associated with a poor prognosis (1). 
Treatment of rheumatic disease with alkylating drugs is 
associated with the development of MDS and hemato- 
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logic malignancies (4), and conversely, patients with 
MDS can develop rheumatic manifestations (5,6). How- 
ever, to date, no study has described the cytogenetic 
abnormalities in patients with rheumatic diseases who 
have developed therapy-related MDS. This study de- 
scribes the MDS and cytogenetic abnormalities that 
occurred in a group of patients with rheumatic disease 
who had been treated with alkylating drugs. 
PATIENTS AND METHODS 
All patients with rheumatic disease who attend our 
clinics and receive immunosuppressive drugs are monitored 
regularly, with monthly complete blood cell counts, for the 
development of hematologic abnormalities. All patients with 
rheumatic disease who had received alkylating drugs and were 
known to have developed MDS over the previous 7 years were 
included in this study. Their hospital charts were reviewed for 
information regarding their rheumatologic diagnosis, as well as 
the type, cumulative dose, and duration of the alkylating drug. 
Additional information regarding cytogenetic abnormalities, 
the type of MDS, and the patient outcome was obtained from 
chart and pathologic review. In each case, treatment with an 
alkylating drug was initiated because of serious complications 
of the disease. 
The classification of MDS has been previously de- 
scribed (7). Cytogenetic studies were performed on cells from 
a bone marrow aspirate obtained during a routine workup for 
the hematologic disorder. In all cases, the bone marrow and 
karyotype were reviewed by a pathologist and cytogeneticist, 
respectively. 
RESULTS 
Table 1 characterizes the patients in this study. 
Five men and 3 women, with a mean age of 56.9 years 
(range 36-75 years), developed MDS over the 7-year 
study period. Their clinical presentations were varied. 
Five presented with cytopenia on routine laboratory 
testing. Two patients presented with increasing fatigue 
related to anemia. Seven patients had received cyclo- 
phosphamide and 1 chlorambucil as their main immuno- 
suppressive drug. The mean cumulative cyclophospha- 
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* Myelodysplastic syndromes (MDS) are defined in ref. 7. CYC = cyclophosphamide; RAEB-T = refractory anemia with excess blasts in 
transformation; MDS-NOS = MDS not otherwise subclassified; CHL = chlorambucil. 
mide dose was 118 gm (SD 16.6 gm), with a mean 
treatment period of 4.4 years (range 2-10 years). The 
chlorambucil-treated patient received a total dose of 6.5 
gm. Of the cyclophosphamide-treated patients, 3 had 
also received 2 other immunosuppressive drugs (meth- 
otrexate and azathioprine in 1, methotrexate and cyclo- 
sporin A in 1, and chlorambucil [total dose 3.6 gm] and 
methotrexate in 1) and 1 had received a different 
immunosuppressive drug (chlorambucil at a total dose 
1.4 gm). 
The mean time from the start of treatment to the 
development of MDS was 8.25 years (range 2-19 years). 
The mean time from the diagnosis of the rheumatic 
disease to the development of MDS was 10.6 years 
(range 7-19 years). The mean time from discontinuation 
of the alkylating drug to development of MDS was 2.4 
years (range 0-4 years). 
Figure 1 shows the karyotype of a patient with 
rheumatoid vasculitis, which necessitated treatment with 
cyclophosphamide. A total cumulative dose of 112.5 gm 
of cyclophosphamide was administered over 3 years. He 
developed refractory anemia with excess blasts 5 years 
after starting cyclophosphamide. The karyotype shows 
deletions of part of the long arms of chromosomes 5 and 
7. He died 8 months after his MDS was diagnosed. In 
Figure 2, a second karyotype is shown, with a deletion of 
part of the long arm of chromosome 5 (5q-). This 
patient had Wegener’s granulomatosis and had received 
a total cumulative dose of 109 gm of cyclophosphamide. 
He died from complications of the MDS 19 years after 
his rheumatologic diagnosis. 
Cytogenetic abnormalities in chromosome 7 oc- 
Figure 1. Karyotype from a patient with rheumatoid arthritis and 
vasculitis, showing deletions of part of the long arm of chromosomes 5 
and 7 (arrows) as well as 2 chromosomes that could not be identified 
(markers; bottom left) and monosomies 12 and 17. These abnormali- 
ties were present in all cells analyzed. 
Figure 2. Karyotpe from a patient with Wegener’s granulomatosis, 
showing a deletion in part of the long arm of chromosome 5 (arrow). 
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curred in 5 patients, while abnormalities in chromosome 
5 occurrcd in 4 patients (the patient described above had 
abnormalities in both chromosome 5 and chromosome 
7). The cytogenetic changes described in these patients 
are characteristic of therapy-related MDS. In contrast, 
the histologic features were frequently minimal. The 
outcome was poor, with 6 of 8 patients dying from 
complications of their MDS. Four of these had changes 
in chromosome 5. 
DISCUSSION 
Up to 80% of individuals with therapy-related 
MDS or therapy-related acute myeloid leukemia have 
loss of chromosomal material from chromosome 5 
and/or chromosome 7 (2,8). In this study, we report the 
types of MDS and cytogenetic abnormalities that oc- 
curred in a group of hospital-based patients with rheu- 
matic diseases after treatment with alkylating drugs. 
While these patients had different indications for treat- 
ment with alkylating drugs, they all had received large 
doses of alkylating agents. Their outcome was poor, 
particularly in those patients with abnormalities of chro- 
mosome 5, in a relatively young population of patients. 
This is consistent with another report of a poor progno- 
sis in cancer patients who developed MDS after treat- 
ment with alkylating drugs (1). Patients with MDS can 
develop rheumatic disease manifestations (5,6), with a 
third of patients developing chromosomal abnormalities 
(5) .  To date, as far as we are aware, there have been no 
reports of cytogenetic abnormalities in chromosome 5 in 
patients with rheumatic disease. This suggests that the 
changes documented herein are likely to be a secondary 
phenomenon related to high cumulative doses of the 
alkylating drugs (4,8). 
We can only speculate as to the duration of risk 
of MDS following discontinuation of the alkylating drug. 
In this study, our patients developed MDS up to 4 years 
after cessation of the alkylating drug, but in patients 
treated for cancer, there have been reports of MDS 
developing up to 12 years after treatment (2,8-10). In 
contrast, one study suggested that there is no increased 
risk of therapy-related MDS 10 years after discontinua- 
tion of treatment (11). Thc actual risk of developing 
MDS in our population of patients treated with alkylat- 
ing drugs is not known; however, followup of our 
patients is ongoing. We are currently following up 24 
patients on a regimen of oral cyclophosphamide and 
over 100 patients who have received intravenous cyclo- 
phosphamide. We are also following up 5 patients being 
treated with chlorambucil. 
Many of these patients have also been treated 
with methotrexate and/or azathioprine. Azathioprine 
may increase the risk of some malignancies. However, in 
rheumatic disease, neither of these compounds has been 
clearly implicated in the development of MDS (12,13). 
We can only suggest that patients who have been treated 
with alkylating drugs and methotrexate or azathioprine 
should be followed up very closely. 
A deletion of the long arm of chromosome 5 
(5q-) in patients with refractory anemia was described 
in 1974, and is now called the 5q- syndrome (8,14,15). 
The chromosome breakpoints vary. However, there is a 
region of overlap that is consistently lost (16). This 
region on 5q contains the genetic information for a large 
number of growth factors and growth factor receptor 
genes, which play an important role in normal myeloid 
growth and differentiation. In addition, the loss of 
heterozygosity at some loci, leading to oncogene expres- 
sion, may be important in the development of MDS (16). 
The findings of this study suggest that high 
cumulative doses of alkylating drugs present a risk for 
the development of MDS, with associated cytogenetic 
abnormalities of chromosomes 5 and/or 7 in patients 
with rheumatic diseases. Long-term hematologic moni- 
toring of patients who have received cumulative doses of 
>lo0 gm of cyclophosphamide is strongly recom- 
mended. The occurrence of hematologic abnormalities 
in patients with rheumatic disease who have received 
high cumulative doses of alkylating drugs may herald the 
onset of MDS. Bone marrow evaluation should include 
cytogenetic studies because these may have diagnostic 
and prognostic implications. 
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